Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 12, 2011, Pages 1464-1471

  Marrie, Ruth Ann ^a   Cutter, Gary ^b   Tyry, Tuula ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

all medical systemic disease; cohort studies; comorbidities; disability; multiple sclerosis; vision

Indexed keywords

ADULT; ARTICLE; CATARACT; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GLAUCOMA; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL VASCULAR DISEASE; RATING SCALE; RISK FACTOR; UVEITIS; VISUAL DISORDER;

EID: 82555171607     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511414041     Document Type: Article

References (42)

1. Rucker JC. Efferent visual dysfunction from multiple sclerosis. Int Ophthalmol Clin. 2007 ; 47: 1-13 (Pubitemid 351326166)
2. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain. 1990 ; 113: 1597-1628
3. Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis?. Ann Neurol. 2005 ; 57: 210-215 (Pubitemid 40179859)
4. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005 ; 4: 111-121 (Pubitemid 40138926)
5. Balcer LJ, Baier ML, Kunkle AM, Rudick RA, Weinstock-Guttman B, Simonian N, et al. Self-reported visual dysfunction in multiple sclerosis: Results from the 25-item national eye institute visual function questionnaire (VFQ-25). Mult Scler. 2000 ; 6: 382-385 (Pubitemid 32106798)
6. Armstrong J The Cost of Blindness: what it means to Canadians. Toronto, Canada: Environics Symposium ; 2004 :
7. Polman C, Uitdehaag BNJ, Klok A-M. Ocular comorbidity in multiple sclerosis. Lancet. 2003 ; 361: 1230
8. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler. 2008 ; 14: 1091-1098
9. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003 ; 290: 2057-2060 (Pubitemid 37430590)
10. Consortium of Multiple Sclerosis Centers. NARCOMS multiple sclerosis registry. http://www.mscare.org/cmsc/CMSC-NARCOMS-Information.html.
11. Marrie RA, Goldman MD. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler. 2007 ; 13: 1176-1182 (Pubitemid 351541422)
12. Kleinbaum DG, Klein M Survival analysis. A self-learning text. 1 st ed. New York, NY: Springer-Verlag, 1997. New York, NY: Springer-Verlag ; 1997 :
13. Allison PD Survival analysis using SAS. A practical guide. Cary, NC: SAS Press ; 1995 :
14. Bramley T, Peeples P, Walt JG, Juhasz M, Hansen JE. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Arch Ophthalmol. 2008 ; 126: 849-856 (Pubitemid 351831337)
15. Clarke PM, Simon J, Cull CA, Holman RR. Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care. 2006 ; 29: 1506-1511 (Pubitemid 44127572)
16. Langelaan M, de Boer MR, van Nispen RMA, Wouters B, Moll AC, van Rens GHMB. Impact of visual impairment on quality of life: A comparison with quality of life in the general population and with other chronic conditions. Ophthalmic Epidemiol. 2007 ; 14: 119-126 (Pubitemid 47026989)
17. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol. 2007 ; 125 (4). 544-550 (Pubitemid 46596727)
18. Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009 ; 28: 34-62
19. DelMonte DW, Bhatti MT. Ischemic optic neuropathy. Int Ophthalmol Clin. 2009 ; 49: 35-62
20. Akiyama H, Meyer JS, Mortel KF, Terayama Y, Thornby JI, Konno S. Normal human aging: Factors contributing to cerebral atrophy. J Neurol Sci. 1997 ; 152: 39-49 (Pubitemid 27469709)
21. Enzinger C, Fazekas F, Matthews PM, Ropele S, Schmidt H, Smith S, et al. Risk factors for progression of brain atrophy in aging: Six-year follow-up of normal subjects. Neurology. 2005 ; 64: 1704-1711 (Pubitemid 40695802)
22. Knopman DS, Mosley TH, Catellier DJ, Sharrett AR. Atherosclerosis Risk in Communities (ARIC) Study. Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology. 2005 ; 65: 876-881 (Pubitemid 41362133)
23. Elkins JS, O'Meara ES, Longstreth WT, Carlson MC, Manolio TA, Johnston SC. Stroke risk factors and loss of high cognitive function. Neurology. 2004 ; 63: 793-799 (Pubitemid 39297636)
24. Pavlik VN, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005 ; 24: 42-50 (Pubitemid 39664107)
25. Jefferson AL, Massaro JM, Wolf PA, Seshadri S, Au R, Vasan RS, et al. Inflammatory biomarkers are associated with total brain volume: The Framingham heart study. Neurology. 2007 ; 68: 1032-1038 (Pubitemid 46569138)
26. Wong TY, Scott IU. Retinal-vein occlusion. N Engl J Med. 2010 ; 363: 2135-2144
27. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
28. Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis. N Engl J Med. 359: 1786-1801
29. Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, et al. Optical coherence tomography in multiple sclerosis: A systematic review and meta-analysis. Lancet Neurol. 2010 ; 9: 921-932
30. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997 ; 50: 1129-1136 (Pubitemid 27477990)
31. Collins JG. Prevalence of selected chronic conditions, united states, 1986-88 National center for health statistics. Vital Health Statistics. 1993 ; 10: 1-87
32. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006 ; 55: 420-426 (Pubitemid 43887028)
33. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993 ; 100: 818-824
34. Donaldson MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: A 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007 ; 144: 812-817.e2
35. Bergmann MM, Byers T, Freedman DS, Mokdad A. Validity of self-reported diagnoses leading to hospitalization: A comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol. 1998 ; 147: 969-977 (Pubitemid 28244168)
36. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 ; 74: 1041-1047
37. Congdon N, Vingerling JR, Klein BE, West S, Friedman DS, Kempen J, et al. Prevalence of cataract and pseudophakia/aphakia among adults in theUnited States. Arch. Ophthalmol. 2004 ; 122: 487-494 (Pubitemid 38456283)
38. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992 ; 99: 1499-1504
39. Gritz DC, Wong IG. Incidence and prevalence of uveitis in northern California. Ophthalmology. 2004 ; 111: 491-500
40. Hyattsville, Maryland: National Center for Health Statistics ; 2006: 1-164.
41. Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM. Risk factors for premature peripheral vascular disease: Results for the National Health and Nutritional Survey, 1999-2002. J. Vasc. Surg. 2006 ; 44: 319-325 (Pubitemid 44142922)
42. Hyattsville, MD: U.S. Department of Health and Human Services ; 2005: 1-535.